Vertex Pharmaceuticals D
D
VRTX
463.82
USD
-8.60
(-1.82%)
مفتوح الان
حجم التداول
26,386
الربح لكل سهم
18
العائد الربحي
-
P/E
-121
حجم السوق
119,192,414,346
الأخبار المقالات
العنوان: Vertex Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.